Harbour BioMed wins China NMPA nod to start Phase 1 of B7H4×CD3 bispecific HBM7004
Harbour BioMed (HKEX: 02142) said on 18 August 2026 that China's National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for HBM7004 in advanced solid tumours, clearing the way for a first-in-human Phase 1 study.
HBM7004 is a novel B7H4×CD3 bispecific antibody built on Harbour BioMed's HBICE® (HCAb-based immune cell engager) platform, designed to redirect T cells against B7H4-expressing tumours. In preclinical work it showed an intratumour, B7H4-dependent pattern of T-cell activation, which the company positions as a route to a wider therapeutic window and improved safety. Management framed the clearance as further evidence of the HBICE® platform's "plug-and-play" versatility for generating T-cell engagers.